Small-cell prostate carcinoma: A retrospective analysis of five newly reported cases

Indian Journal of Urology

Volumn 25, Issue 2, 2009, Pages 259-263

  Brownback, Kyle ^a   Renzulli, Joseph ^a   DeLellis, Ronald ^a   Myers, James ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Neuroendocrine carcinoma; Prostatic neoplasm; Small cell carcinoma

Indexed keywords

ANTIANDROGEN; CARBOPLATIN; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; ESTRAMUSTINE; ETOPOSIDE; FLUTAMIDE; HYDROCORTISONE; LEUPRORELIN; METHOTREXATE; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ANAMNESIS; ARTICLE; BALLOON CATHETER; BONE METASTASIS; BONE SCINTISCANNING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOMATOUS MENINGITIS; CLINICAL ARTICLE; CLINICAL FEATURE; DEATH; DRUG MEGADOSE; HOSPICE CARE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; SMALL CELL CARCINOMA; ULTRASOUND;

EID: 67651222173     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.52940     Document Type: Article

References (22)

1. Yashi M, Terauhi F, Nukui A, Ochi M, Yuzawa M, Hara Y, et al. Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: A case report and short literature review. Urol Oncol 2006;24:313-317 (Pubitemid 43963405)
2. Abbas F, Civantos F, Benedetto P, Soloway MS. Small cell carcinoma of the bladder and prostate. Urology 1995;46:617-630
3. Rubenstein JH, Katin MJ, Mangano MM, Dauphin J, Salenius SA, Dosoretz DE, et al. Small cell anaplastic carcinoma of the prostate: Seven new cases, review of the literature and discussion of a therapeutic strategy. Am J Clin Onc 1997:20;376-380 (Pubitemid 27329571)
4. Tanaka M, Suzuki Y, Takaoka K, Suzuki N, Murakami S, Matsuzaki O, et al. Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol 2001;8:431-436 (Pubitemid 34225095)
5. Papandeou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin On 2002;20:3072-3080 (Pubitemid 34791096)
6. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NE. Small cell carcinoma of the prostate, Part I: A clinicopathologic study of 20 cases. Cancer 1987;59:1803-1809
7. Evans AJ, Humphrey PA, Belanai J, van der Kwast TH, Srigley JR. Large cell neuroendocrine carcinoma of prostate: A clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 2006;30:684-693
8. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999;39:135-148
9. Yahsi M, Kurokawa S, Tokue A. Prostatic small-cell neuroendocrine carcinoma with disease progression monitored by measurement of serum progastrin-releasing peptide. BJU Int 2000;86:1091-1092 (Pubitemid 32006179)
10. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjolnerod OK, Waldum HL Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997;30:1-6.
11. Sciarra A, Mariotti G, Gentile V, Voria G, Pastore A, Monti S, et al. Neuroendocrine differentiation in human prostatic tissue: Is it detectable and treatable? BJU Int 2003;91:438-445
12. Angelsen A, Syversen U, Stridsberg M, Haugen OA, Mjolnerod OK, Waldum Hl. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate 1997;31:110-117 (Pubitemid 27188140)
13. Kinebuchi Y, Noguchi W, Irie K, Nakayama T, Kato H, Nishizawa O. Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembyonic antigen without elevation of prostrate-specific antigen: A case report. Int J Urol 2007;14:147-149 (Pubitemid 46121953)
14. Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 1998;51:585-589 (Pubitemid 28186211)
15. Abrahamsson PA. Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate Suppl 1996;6:3-8. (Pubitemid 26112281)
16. Petraki C, Vaslamatzis M, Petraki K, Revelos K, Alevizopoulos N, Papanastasiou P, et al. Prostate cancer with small-cell morphology: An immunophenotypic subdivision. Scand J Urol Nephrol 2005;39:455-463 (Pubitemid 41722025)
17. Clegg N, Ferguson C, True LD, Arnold H, Moorman A, Quinn JE, et al. Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate 2003;55:55-64. (Pubitemid 36397745)
18. Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S, et al. Small cell carcinoma of the prostate: An immunohistochemical study. Am J Surg Pathol 2006;30:705-712 (Pubitemid 44264995)
19. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufle P, Aparicio T, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351-1355
20. Dimopoulos MA, Panopoulos C, Bamia C, Deliveliotis C, Alivizatos G, Pantazopoulos D, et al. Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 1997;50:754-758 (Pubitemid 27494998)
21. Aoki H, Ishidoya S, Ito A, Endoh M, Shimazui T, Arai Y. Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate. Int J Urol 2006;13:1254-1258 (Pubitemid 44410923)
22. Spieth ME, Lin YG, Nguyen TT. Diagnosing and treating small-cell carcinomas of prostatic origin. Clin Nucl Med 2002;27:11-17